MedPath

Sitagliptin Use and its Continuous Glycemic Control Effcets in Japanese patients with type 2 diabetes in Saitama

Not Applicable
Conditions
Type 2 diabetes
Registration Number
JPRN-UMIN000005076
Lead Sponsor
Dokkyo Medical University,Koshigaya Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with type 1 diabetes 2. Renal impairment (Serum creatinine more than 1.5 mg/dl in men or 1.3 mg/dl in women) 4. Patients who undergo surgery 5. Preganat women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. To achieve HbA1c less than 7.0% (JDS values) at 12 weeks after treatment with sitagliptin 2. The time to monotherapy failure
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath